BackPyxis Oncology Overview
Pyxis Oncology Inc

Pyxis Oncology Target Price

See Pyxis Oncology's analyst price targets ($6.5) vs the current share price.

Get informed when a big investor buys or sells

+ Follow

Share Price

$2.99

Average Target Price

$6.50117.4% upside

2 analysts in the last 4 months

High: $7 | Low: $6

Analyst Recommendations

No recommendations in the last 4 months.

Revenue & Income Forecast

Analysts' Target Prices

DateAnalystPrice TargetCurrent Upside/Downside
2026-07-02Leerink PartnersJeffrey La Rosa$7134.1% upsideOpen
2026-05-05WedbushRobert Driscoll$6100.7% upsideOpen
2025-12-18RBC CapitalLeonid Timashev$567.2% upsideOpen
2025-11-24StephensSudan Loganathan$8167.6% upsideOpen
2025-11-04GuggenheimBradley Canino$7134.1% upsideOpen
2025-09-04Guggenheim$567.2% upsideOpen
2024-08-16H.C. WainwrightSwayampakula Ramakanth$7134.1% upsideOpen
2024-08-07Stifel NicolausBradley Canino$10234.4% upsideOpen
2024-05-07JefferiesFarzin Haque$10234.4% upsideOpen

Pyxis Oncology (PYXS) FAQ

The latest target price for PYXS is $6.5. Investors often review this figure alongside Pyxis Oncology's historical trend and sector peers before judging valuation or financial health.

Pyxis Oncology trades near $2.99 while the consensus target sits at $6.5 (117.4% upside). Targets are estimates based on earnings forecasts and valuation models; they change when analysts update ratings or revise models. Compare the average with the high and low targets for a fuller picture.

After noting PYXS's target price ($6.5), review year-over-year change, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.

This page's peer comparison chart is the fastest way to stack Pyxis Oncology's target price against similar Healthcare names. You can also browse sector and industry screens on Stockcircle for a broader set of Healthcare companies and their key multiples and fundamentals.